首页> 外文期刊>Expert opinion on biological therapy >Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia
【24h】

Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia

机译:血管内皮生长因子抑制剂在病理性近视继发性脉络膜新生血管形成中的使用和治疗方法

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Myopic choroidal neovascularization (CNV) is the most common cause of CNV in those under 50years of age. It is a significant cause of visual loss in those with pathologic myopia. The current standard of care involves therapy with intravitreal inhibitors of vascular endothelial growth factor (VEGF).Areas Covered: The epidemiology of myopia, high myopia, pathologic myopia, and myopic CNV is reviewed, along with a brief discussion of historical treatments. The pharmacology of the three most commonly used anti-VEGF agents is discussed, with an emphasis on the licensed drugs, ranibizumab and aflibercept. A comprehensive clinical approach to diagnosis and treatment of myopic CNV is presented.Expert Opinion: The current standard of care for myopic CNV is intravitreal inhibition of VEGF, with ranibizumab and aflibercept licensed for intraocular use. The diagnosis, OCT features of disease activity and retreatment algorithm for myopic CNV is different from wet age-related macular degeneration. In the long-term, myopic CNV may be associated with gradual, irreversible visual loss due to progressive chorioretinal atrophy, for which there is currently no treatment.
机译:简介:近视脉络膜新生血管(CNV)是50岁以下人群中CNV的最常见原因。这是病理性近视患者视力丧失的重要原因。当前的护理标准包括使用玻璃体内血管内皮生长因子(VEGF)抑制剂进行治疗。涵盖范围:对近视,高度近视,病理性近视和近视CNV的流行病学进行了回顾,并简要讨论了历史治疗方法。讨论了三种最常用的抗VEGF药物的药理学,重点是许可药物兰尼单抗和aflibercept。提出了一种综合的近视CNV诊断和治疗的临床方法。专家意见:目前治疗近视CNV的标准是玻璃体内抑制VEGF,兰尼单抗和aflibercept许可用于眼内使用。近视CNV的诊断,疾病活动的OCT特征和再治疗算法与湿性老年性黄斑变性不同。从长远来看,近视CNV可能与进行性脉络膜视网膜萎缩引起的逐渐的,不可逆的视力丧失有关,目前尚无治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号